An observational study in Aortic Stenosis, Mitral Regurgitation and Tricuspid Regurgitation, sponsored by Josep Rodes-Cabau. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Josep Rodes-Cabau · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Aortic stenosis is a condition in which the aortic valve becomes narrow and does not open properly, making it harder for the heart to pump blood to the body. Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure commonly used to treat this condition, especially in older patients or patients at high surgical risk.
Many patients undergoing TAVI also have leakage of the mitral valve and/or tricuspid valve. These valve problems can cause symptoms such as shortness of breath, fatigue, swelling, heart failure, and repeated hospitalizations. Patients with multiple valve diseases generally have worse outcomes and are more difficult to treat.
In some patients, mitral or tricuspid valve leakage improves after TAVI because the heart works better once the aortic valve has been treated. However, in other patients, the leakage remains severe and continues to affect their health and quality of life. New minimally invasive treatments are now available to repair or replace the mitral and tricuspid valves, but doctors still do not know the best order or timing for these procedures.
This study aims to evaluate a treatment algorithm for patients with severe aortic stenosis and significant mitral and/or tricuspid valve leakage. The proposed approach follows current clinical guidelines and uses a stepwise strategy. Patients will first undergo TAVI, followed by reassessment of the mitral and tricuspid valves. If important valve leakage persists after TAVI, additional minimally invasive procedures may be considered to treat the mitral or tricuspid valve.
The study will include patients with severe aortic stenosis and moderate-to-severe or severe mitral and/or tricuspid regurgitation. Researchers will collect information about patient symptoms, heart imaging results, procedures, hospitalizations, quality of life, and clinical outcomes during follow-up.
The main goal of the study is to evaluate whether this staged treatment approach is safe, feasible, and effective in improving patient outcomes. Researchers will also assess whether the strategy can reduce hospitalizations for heart failure and improve symptoms, daily functioning, and quality of life.
The results of this study may help doctors better manage patients with multiple valve diseases and provide a more personalized and structured treatment approach for this complex group of patients.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
This study's planned enrollment of 300 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Browse Aortic Valve Stenosis studies →Josep Rodes-Cabau is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of adult patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) who also present with significant concomitant mitral regurgitation and/or tricuspid regurgitation. The study will mainly include elderly patients and patients considered at intermediate, high, or prohibitive surgical risk for conventional open-heart surgery.
Eligible participants will have moderate-to-severe or severe mitral and/or tricuspid valve regurgitation identified by echocardiography before TAVI. Patients will be evaluated and treated according to a staged transcatheter treatment algorithm based on current clinical guidelines and the evolution of valve disease following TAVI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with severe aortic stenosis (AS) and significant mitral regurgitation (MR) undergoing TAVI followed, if needed, by mitral intervention (M-TEER).
Patients with severe AS and significant tricuspid regurgitation (TR) undergoing TAVI followed, if needed, by tricuspid intervention (T-TEER).
Patients with severe AS, MR, and TR undergoing staged triple-valve transcatheter therapy.
All-cause mortality or re-hospitalization for worsening heart failure
Composite of all-cause mortality or re-hospitalization for worsening heart failure at a minimum of 1 year following the TAVI procedure
Time frame: Minimum of 1 year
All-cause mortality or re-hospitalization for worsening heart failure
Composite of all-cause mortality or re-hospitalization for worsening heart failure at 1-year follow-up.
Time frame: 1 Year
All-cause mortality or re-hospitalization for worsening heart failure
Composite of all-cause mortality or re-hospitalization for worsening heart failure at 2-year follow-up
Time frame: 2 year
All-cause mortality or re-hospitalization for worsening heart failure
Composite of all-cause mortality or re-hospitalization for worsening heart failure at 3-year follow-up.
Time frame: 3 year
All-cause mortality or re-hospitalization for worsening heart failure
Composite of all-cause mortality or re-hospitalization for worsening heart failure at 4-year follow-up.
Time frame: 4 year
All-cause mortality or re-hospitalization for worsening heart failure
Composite of all-cause mortality or re-hospitalization for worsening heart failure at 5-year follow-up.
Time frame: 5 year
All-cause mortality
All-cause mortality at 1 year
Time frame: 1 year
All-cause mortality
All-cause mortality at 2 year
Time frame: 2 year
All-cause mortality
All-cause mortality at 3 year
Time frame: 3 year
All-cause mortality
All-cause mortality at 4 year
Time frame: 4 year
All-cause mortality
All-cause mortality at 5 year
Time frame: 5 year
Heart failure re-hospitalization
Heart failure re-hospitalization at 1 year
Time frame: 1 year
Heart failure re-hospitalization
Heart failure re-hospitalization at 2 year
Time frame: 2 year
Heart failure re-hospitalization
Heart failure re-hospitalization at 3 year
Time frame: 3 year
Heart failure re-hospitalization
Heart failure re-hospitalization at 4 year
Time frame: 4 year
Heart failure re-hospitalization
Heart failure re-hospitalization at 5 year
Time frame: 5 year
Cardiovascular mortality
Cardiovascular mortality at 1 year
Time frame: 1 year
Cardiovascular mortality
Cardiovascular mortality at 2 year
Time frame: 2 year
Cardiovascular mortality
Cardiovascular mortality at 3 year
Time frame: 3 year
Cardiovascular mortality
Cardiovascular mortality at 4 year
Time frame: 4 year
Cardiovascular mortality
Cardiovascular mortality at 5 year
Time frame: 5 year
All-cause mortality or heart failure re-hospitalization
Evaluation of the composite outcome (all-cause mortality or heart failure re-hospitalization) at 1-year follow-up compared with a historical cohort.
Time frame: 1 year
MR severity
MR severity at 1 year
Time frame: 1 year
MR severity
MR severity at 2 year
Time frame: 2 year
MR severity
MR severity at 3 year
Time frame: 3 year
MR severity
MR severity at 4 year
Time frame: 4 year
MR severity
MR severity at 5 year
Time frame: 5 year
TR severity
TR severity at 1 year
Time frame: 1 year
TR severity
TR severity at 2 year
Time frame: 2 year
TR severity
TR severity at 3 year
Time frame: 3 year
TR severity
TR severity at 4 year
Time frame: 4 year
TR severity
TR severity at 5 year
Time frame: 5 year
LVEF
LVEF at 1 year
Time frame: 1 year
LVEF
LVEF at 2 year
Time frame: 2 year
LVEF
LVEF at 3 year
Time frame: 3 year
LVEF
LVEF at 4 year
Time frame: 4 year
LVEF
LVEF at 5 year
Time frame: 5 year
No study locations are listed for this record.
Plan to share: No — Individual participant data (IPD) will not be publicly shared due to patient confidentiality and privacy considerations, as well as institutional and ethical restrictions governing the use of clinical research data.
Start is estimated for Jan 2027; primary completion for Jun 2029, 29 months later.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 29 months is below that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Josep Rodes-Cabau